Advertisement

Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer

Abstract

Purpose

The aims of this longitudinal model-based meta-analysis (MBMA) were to indirectly compare the time courses of survival probabilities and to identify corresponding potential significant covariates across approved drugs in patients with castration-resistant prostate cancer (CRPC).

Methods

A systematic literature review for monotherapy studies in patients with CRPC was conducted up to August 8, 2018. The time courses of progression-free survival (PFS) and overall survival (OS) were fitted with parametric survival models. Covariate analyses were performed to determine the impact of treatment drugs, dosing regimens, and patient characteristics on the survival probabilities. Simulations were carried out to quantify the magnitude of covariate effects.

Results

A total of 146 studies including clinical trials and real-world data on longitudinal survival probabilities in 20,712 patients with CRPC were included in our meta-database. The time courses of PFS and OS probabilities were best described by the log-logistic model. There was no significant difference in median OS and PFS between docetaxel, cabazitaxel, abiraterone acetate, and enzalutamide. There was no significant dose-response relationship in PFS or OS for docetaxel at 50 to 120 mg/m2 every 3 weeks (Q3W) and cabazitaxel at 20 to 25 mg/m2 Q3W. Model-based simulations indicated that PFS probability was associated with chemotherapy, Gleason score, and baseline prostate-specific antigen (BLPSA), while OS probability was associated with chemotherapy, Gleason score, visceral metastasis, Eastern Cooperative Oncology Group performance status, and BLPSA.

Conclusion

Our modeling and simulation framework can be applied to support indirect comparison, dose selection, and go/no-go decision-making for new agents targeting CRPC.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30

  2. 2.

    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132

  3. 3.

    D’Amico AV (2014) US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol Off J Am Soc Clin Oncol 32(4):362–364

  4. 4.

    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

  5. 5.

    Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS (2013) Castration-resistant prostate cancer: AUA Guideline. J Urol 190(2):429–438

  6. 6.

    Cookson MS, Lowrance WT, Murad MH, Kibel AS (2015) Castration-resistant prostate cancer: AUA guideline amendment. J Urol 193(2):491–499

  7. 7.

    Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS (2016) Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol 195(5):1444–1452

  8. 8.

    Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS (2018) Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol 200(6):1264–1272

  9. 9.

    U.S. Food and Drug Administration Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. 2018. http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf

  10. 10.

    Scher HI, Warren M, Heller G (2007) The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 13(5):1488–1492

  11. 11.

    Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ (2009) Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(17):2766–2771

  12. 12.

    Gomella LG, Oliver Sartor A (2014) The current role and limitations of surrogate endpoints in advanced prostate cancer. Urol Oncol 32(1):28.e21–28.e29

  13. 13.

    Armstrong AJ, Febbo PG (2009) Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist 14(8):816–827

  14. 14.

    Chen W, Li L, Ji S, Song X, Lu W, Zhou T (2019) Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis. Eur J Clin Pharmacol 75(11):1521–1532

  15. 15.

    Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol Off J Am Soc Clin Oncol 26(7):1148–1159

  16. 16.

    Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I (2019) Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther 105(4):899–911

  17. 17.

    Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, Visser SAG (2019) Model-informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol 8(2):87–96

  18. 18.

    Ait-Oudhia S, Straubinger RM, Mager DE (2012) Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res 29(10):2833–2844

  19. 19.

    Ocampo-Pelland AS, Gastonguay MR, French JF, Riggs MM (2016) Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data. J Pharmacokinet Pharmacodyn 43(2):191–206

  20. 20.

    Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2010) Disease progression meta-analysis model in Alzheimer’s disease. Alzheimers Dement 6(1):39–53

  21. 21.

    William-Faltaos D, Chen Y, Wang Y, Gobburu J, Zhu H (2013) Quantification of disease progression and dropout for Alzheimer’s disease. Int J Clin Pharmacol Ther 51(2):120–131

  22. 22.

    Wang X, Shang D, Ribbing J, Ren Y, Deng C, Zhou T, Guo F, Lu W (2012) Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second. Eur J Clin Pharmacol 68(8):1157–1166

  23. 23.

    Mandema JW, Boyd RA, DiCarlo LA (2011) Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis. Clin Pharmacol Ther 90(6):820–827

  24. 24.

    Gibbs JP, Fredrickson J, Barbee T et al (2012) Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J Clin Pharmacol 52(10):1494–1505

  25. 25.

    Ren YP, Xie RJ, Marshall S, Li L, Zhou TY, Lu W (2015) Model-based meta-analysis of the effects of non-selective and alpha1-selective GABAA receptor agonists in healthy volunteers. Eur J Clin Pharmacol 71(10):1209–1221

  26. 26.

    Dodds MG, Salinger DH, Mandema J, Gibbs JP, Gibbs MA (2013) Clinical trial simulation to inform phase 2: comparison of concentrated vs. distributed first-in-patient study designs in psoriasis. CPT Pharmacometrics Syst Pharmacol 2:e58

  27. 27.

    Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D (2005) Model-based development of gemcabene, a new lipid-altering agent. AAPS J 7(3):E513–E522

  28. 28.

    Halabi S, Kelly WK, Zhou H et al (2014) The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): a meta-analysis of five phase III trials. J Clin Oncol 32:5s

  29. 29.

    Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB, Generali D (2016) Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer 61:111–121

  30. 30.

    Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA (2017) Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget 8(48):84572–84578

  31. 31.

    Iacovelli R, Altavilla A, Procopio G, Bracarda S, Santoni M, Cascinu S, Cortesi E (2013) Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. Prostate Cancer Prostatic Dis 16(4):323–327

  32. 32.

    Ahn JE, French JL (2010) Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37(2):179–201

  33. 33.

    Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Prog Biomed 75(2):85–94

  34. 34.

    Mandema JW, Gibbs M, Boyd RA, Wada DR, Pfister M (2011) Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin Pharmacol Ther 90(6):766–769

  35. 35.

    Mahmud S, Franco E, Aprikian A (2004) Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90(1):93–99

  36. 36.

    King CR (2016) The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol 121(2):199–203

  37. 37.

    Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85(3):686–692

  38. 38.

    Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB (2015) What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 115(3):295–300

  39. 39.

    Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, de Placido S, di Lorenzo G (2013) Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol 9(6):889–897

  40. 40.

    Tomioka A, Tanaka N, Yoshikawa M et al (2014) Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol 14:33

  41. 41.

    Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES (2017) Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol 9(8):565–573

  42. 42.

    Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 32(7):671–677

  43. 43.

    Mottet N, Clarke N, De Santis M, Zattoni F, Morote J, Joniau S (2015) Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? BJU Int 115(3):364–372

  44. 44.

    Oosterlinck W, Mattelaer J, Derde MP, Kaufman L (1995) Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients. Acta Urol Belg 63(3):1–9

  45. 45.

    Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D, de Giorgi U (2014) Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer 21(3):487–493

  46. 46.

    Liao SG, Cheng HH, Lei Y (2016) C-Reactive protein is a prognostic marker for patients with castration-resistant prostate cancer. Oncol Res Treat 39(5):266–271

  47. 47.

    Oudard S, Fizazi K, Sengelov L et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol Off J Am Soc Clin Oncol 35(28):3189–3197

  48. 48.

    Tan PS, Haaland B, Montero AJ, Kyriakopoulos CE, Lopes G (2014) Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison. Clin Med Insights Oncol 8:29–36

  49. 49.

    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R (2018) Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol 73(6):834–844

  50. 50.

    Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES (2014) The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 66(4):646–652

  51. 51.

    Miyake H, Hara T, Ozono S, Fujisawa M (2017) Impact of prior use of an androgen receptor-Axis-targeted (ARAT) agent with or without subsequent taxane therapy on the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 15(2):e217–e222

  52. 52.

    Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV (2014) Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65(1):30–36

  53. 53.

    Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY (2015) Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis 18(2):122–127

  54. 54.

    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154

  55. 55.

    Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate Cancer-PROSELICA. J Clin Oncol Off J Am Soc Clin Oncol 35(28):3198–3206

  56. 56.

    Oyinlola JO, Campbell J, Kousoulis AA (2016) Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res 16:299

  57. 57.

    Bate A, Juniper J, Lawton AM, Thwaites RM (2016) Designing and incorporating a real world data approach to international drug development and use: what the UK offers. Drug Discov Today 21(3):400–405

  58. 58.

    Liu Q, Ramamoorthy A, Huang SM (2019) Real-world data and clinical pharmacology: a regulatory science perspective. Clin Pharmacol Ther 106(1):67–71

  59. 59.

    Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM (2016) Real-world evidence - what is it and what can it tell us? N Engl J Med 375(23):2293–2297

Download references

Author information

Li L, Zhou TY, Lu W, Chen WJ, Ji SM, and Song XY designed the research; Chen WJ, Li L, and Ji SM performed the research; Chen WJ, Li L, and Song XY analyzed the data; Chen WJ, Li L, and Zhou TY wrote the article.

Correspondence to Liang Li or Tianyan Zhou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

The views expressed in this paper are those of the authors and do not necessarily represent those of the China National Medical Products Administration.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 22908 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, W., Li, L., Ji, S. et al. Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer. Eur J Clin Pharmacol (2020) doi:10.1007/s00228-020-02829-9

Download citation

Keywords

  • Model-based meta-analysis
  • Castration-resistant prostate cancer
  • Progression-free survival
  • Overall survival
  • Longitudinal data